PROCEPT BioRobotics Corp

PROCEPT BioRobotics Corp (PRCT) priced its initial public offering on Sep 16, 2021 at $25.00 per share, above its $22.00–$24.00 range, raising $163.9M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $1.06B. BofA Securities was lead-left underwriter, joined by Goldman Sachs, TD Cowen and Guggenheim and others. Latham & Watkins advised the company and Cooley advised the underwriters.

PROCEPT BioRobotics Corp is a commercial-stage surgical robotics company focused on urology. It makes and sells the AquaBeam Robotic System, an image-guided system delivering Aquablation therapy for benign prostatic hyperplasia (BPH) through minimally invasive surgery.

Status

IPO

Ticker

PRCT

Exchange

Nasdaq Global Market

Priced

Sep 16, 2021

IPO price

$25.00

Price range

$22.00–$24.00

Raised

$163.9M

Market cap at IPO price

$1.06B

First filed

Aug 18, 2021

Underwriters

BofA Securities, Goldman Sachs, TD Cowen, Guggenheim and Leerink Partners

Company counsel

Latham & Watkins

Underwriters' counsel

Cooley

Sector

Healthcare

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.